Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sciatic injury induced long intergenic non-coding RNA upregulator of SOX11 (SILC1)
- Target
- SILC1
- Molecular classification
- Long non-coding RNA, lincRNA (long intergenic non-coding RNA), Non-protein coding gene
01
Overview
SILC1 (Sciatic injury induced lincRNA upregulator of SOX11; also named FLJ30594, LOC150622) is a long non-coding RNA, highly expressed in neural tissue and induced rapidly following neuronal activity such as learning or nerve injury[4][7]. SILC1 acts in *cis* to activate the transcription factor SOX11, triggering a neuronal growth-associated transcriptional program that facilitates nerve regeneration and efficient memory formation[4]. SILC1 is conserved in mammals, expressed prominently in the hippocampus, and is important for spatial learning. Its expression declines during aging and in models of Alzheimer’s disease, suggesting involvement in neurodegenerative conditions. SILC1 is not a receptor, enzyme, or transporter, and no drugs currently target this molecule. It serves primarily as a regulatory RNA that modulates gene expression in neurons and acts as a potential biomarker of neuronal regenerative capacity[4][7].
- Other names
- FLJ30594LOC150622Silc1
02
Biological functions
Regulation of gene expression (SOX11 activation)Neuronal regenerationImmediate-early gene response (rapid induction in learning contexts)Promotion of neuronal growth-associated transcriptional programs
03
Disease associations
Neurodegenerative disease (levels decline in Alzheimer’s models)Nerve injury (regulation of axon regeneration after peripheral nerve injury)Learning and memory (required for efficient spatial learning)
04
Biomarkers
SILC1 levels (potential biomarker for regenerative activity and neuronal plasticity)
Beyond the preview
Go deeper on Sciatic injury induced long intergenic non-coding RNA upregulator of SOX11 (SILC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sciatic injury induced long intergenic non-coding RNA upregulator of SOX11 (SILC1).